Oppenheimer Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.09M | Buy |
13,752
+1,899
| +16% | +$143K | 0.01% | 730 |
|
|
2026
Q1 | $890K | Buy |
11,853
+589
| +5% | +$46.5K | 0.01% | 753 |
|
|
2025
Q4 | $891K | Buy |
+11,264
| New | +$848K | 0.01% | 701 |
|
|
2024
Q3 | – | Sell |
-5,777
| Closed | -$275K | – | 1189 |
|
|
2024
Q2 | $275K | Sell |
5,777
-4,049
| -41% | -$166K | ﹤0.01% | 998 |
|
|
2024
Q1 | $426K | Sell |
9,826
-723
| -7% | -$34.5K | 0.01% | 876 |
|
|
2023
Q4 | $534K | Sell |
10,549
-419
| -4% | -$20.1K | 0.01% | 849 |
|
|
2023
Q3 | $498K | Sell |
10,968
-51
| -0.5% | -$2.1K | 0.01% | 848 |
|
|
2023
Q2 | $452K | Sell |
11,019
-36
| -0.3% | -$1.38K | 0.01% | 882 |
|
|
2023
Q1 | $395K | Buy |
11,055
+686
| +7% | +$25.8K | 0.01% | 901 |
|
|
2022
Q4 | $392K | Sell |
10,369
-465
| -4% | -$19.6K | 0.01% | 912 |
|
|
2022
Q3 | $479K | Sell |
10,834
-69
| -0.6% | -$2.91K | 0.01% | 846 |
|
|
2022
Q2 | $403K | Sell |
10,903
-92
| -0.8% | -$3.47K | 0.01% | 909 |
|
|
2022
Q1 | $407K | Buy |
10,995
+1,213
| +12% | +$39.7K | 0.01% | 962 |
|
|
2021
Q4 | $297K | Sell |
9,782
-1,100
| -10% | -$34.6K | ﹤0.01% | 1077 |
|
|
2021
Q3 | $365K | Buy |
10,882
+165
| +2% | +$6.22K | 0.01% | 1007 |
|
|
2021
Q2 | $427K | Sell |
10,717
-219
| -2% | -$8.58K | 0.01% | 993 |
|
|
2021
Q1 | $491K | Buy |
10,936
+746
| +7% | +$41.6K | 0.01% | 918 |
|
|
2020
Q4 | $577K | Sell |
10,190
-1,086
| -10% | -$54.1K | 0.01% | 841 |
|
|
2020
Q3 | $535K | Sell |
11,276
-671
| -6% | -$37.3K | 0.01% | 796 |
|
|
2020
Q2 | $705K | Sell |
11,947
-276
| -2% | -$15.4K | 0.01% | 699 |
|
|
2020
Q1 | $577K | Sell |
12,223
-440
| -3% | -$24.5K | 0.01% | 688 |
|
|
2019
Q4 | $765K | Sell |
12,663
-305
| -2% | -$18.2K | 0.02% | 699 |
|
|
2019
Q3 | $777K | Sell |
12,968
-845
| -6% | -$55.1K | 0.02% | 686 |
|
|
2019
Q2 | $888K | Sell |
13,813
-787
| -5% | -$55.6K | 0.02% | 651 |
|
|
2019
Q1 | $1.19M | Sell |
14,600
-193
| -1% | -$12.4K | 0.03% | 559 |
|
|
2018
Q4 | $800K | Sell |
14,793
-346
| -2% | -$17.6K | 0.02% | 631 |
|
|
2018
Q3 | $781K | Sell |
15,139
-6,595
| -30% | -$310K | 0.02% | 685 |
|
|
2018
Q2 | $905K | Sell |
21,734
-1,204
| -5% | -$53.4K | 0.02% | 623 |
|
|
2018
Q1 | $1.01M | Buy |
22,938
+804
| +4% | +$40.8K | 0.03% | 596 |
|
|
2017
Q4 | $1.12M | Hold |
22,134
| – | – | 0.03% | 563 |
|
|
2017
Q3 | $1.12M | Buy |
22,134
+632
| +3% | +$33.1K | 0.03% | 566 |
|
|
2017
Q2 | $1.09M | Sell |
21,502
-1,367
| -6% | -$63.7K | 0.03% | 555 |
|
|
2017
Q1 | $919K | Buy |
+22,869
| New | +$1.03M | 0.03% | 597 |
|
Other funds holding IONS
Oppenheimer Asset Management's IONS Position: Q2 2026 in Review
Oppenheimer Asset Management increased its Ionis Pharmaceuticals (IONS) stake by 16% in Q2 2026, buying an estimated $143K and bringing the position to 13,752 shares worth $1.09M. The position accounts for 0.01% of the portfolio, ranked #730.
Oppenheimer Asset Management first reported a position in IONS in Q1 2017 and has held it in 33 quarters since. The position peaked at $1.19M in Q1 2019. 515 funds tracked by Wall St. Rank hold IONS as of Q2 2026.
- Oppenheimer Asset Management held 13,752 shares of Ionis Pharmaceuticals worth $1.09M as of Q2 2026.
- Oppenheimer Asset Management bought 1,899 Ionis Pharmaceuticals shares in Q2 2026, an estimated $143K.
- Ionis Pharmaceuticals made up 0.01% of Oppenheimer Asset Management's portfolio in Q2 2026, its #730 holding.
- Oppenheimer Asset Management first reported a position in Ionis Pharmaceuticals in Q1 2017 and has held it in 33 quarters since.
- Oppenheimer Asset Management's Ionis Pharmaceuticals position peaked at $1.19M in Q1 2019.
- 515 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.
Based on Oppenheimer Asset Management's 13F filing for Q2 2026, filed 3 Aug 2026.